Literature DB >> 14527092

Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943.

A Furuya1, N Kato, S Jingu, M Akimoto, O Kasai, T Suwa, M Sato, H Ogata.   

Abstract

The prediction performances of population pharmacokinetic-pharmacodynamic analysis of the two methods (a stepwise and a simultaneous estimations) were evaluated with respect to their accuracies and precisions. A study was designed to investigate the safety and efficacy of TS-943 by a 4 hours constant infusion in 36 healthy male subjects. Population analysis was performed using pharmacokinetic and pharmacodynamic models with NONMEM. The mean of the prediction error (MPE) and the root mean squared error (RMSE) served as a measure of accuracy and precision. In addition, a bootstrap validation was also performed. The results indicate that those population pharmacokinetic-pharmacodynamic parameters for the two methods were comparable. The results of simultaneous estimations are similar to those obtained using a stepwise estimation. The mean parameter estimates obtained with the additional 200 bootstrap replicates of data were within 15% of those obtained with the final model in both methods. The present results demonstrated that the accuracy of pharmacodynamic evaluations using a stepwise end a simultaneous estimations was comparable.

Mesh:

Substances:

Year:  2003        PMID: 14527092     DOI: 10.1007/BF03190485

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

1.  Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects.

Authors:  A Furuya; N Kato; S Jingu; M Akimoto; S Higuchi; T Suwa; H Ogata
Journal:  Clin Pharmacol Ther       Date:  2000-05       Impact factor: 6.875

Review 2.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

3.  Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.

Authors:  I F Trocóniz; T H Naukkarinen; H M Ruottinen; U K Rinne; A Gordin; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  1998-07       Impact factor: 6.875

4.  Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.

Authors:  J B Schwartz; D Verotta; L B Sheiner
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

Review 5.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.

Authors:  H Takama; H Tanaka; T Sudo; T Tamura; Y Tanigawara
Journal:  Cancer Chemother Pharmacol       Date:  2001-05       Impact factor: 3.333

7.  Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans.

Authors:  M T Marino; B G Schuster; R P Brueckner; E Lin; A Kaminskis; K C Lasseter
Journal:  J Clin Pharmacol       Date:  1998-03       Impact factor: 3.126

8.  Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model.

Authors:  J Parke; B G Charles
Journal:  Eur J Clin Pharmacol       Date:  2000-09       Impact factor: 2.953

9.  Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.

Authors:  C Deschamps; C Dubruc; F Mentre; P Rosenzweig
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

10.  Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.

Authors:  J S Barrett; G Murphy; K Peerlinck; I De Lepeleire; R J Gould; D Panebianco; E Hand; H Deckmyn; J Vermylen; J Arnout
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.